From the Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, Cleveland, OH.
Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic, Cleveland, OH.
Cardiol Rev. 2019 Nov/Dec;27(6):302-307. doi: 10.1097/CRD.0000000000000267.
From the bedside of patients contributing samples to large genome-wide association studies for atrial fibrillation (AF), over 100 AF risk loci have been identified. The top locus is near a gene implicated in pulmonary vein formation; the ostia of the pulmonary veins harbor initiating triggers of AF, and isolation of these areas is the cornerstone of ablation therapies for AF. Transcriptomic studies suggest that AF is associated with impaired or overwhelmed responses to cell stress. A dual risk model proposes that in genetically-susceptible individuals, inadequate transcriptional responses to stress predispose to AF in later life. Drugs targeting metabolic, oxidative, or protein handling stress may be novel upstream agents to bring back to the bedside for study in the prevention of AF.
从参与大规模全基因组关联研究心房颤动 (AF) 的患者床边,已经确定了 100 多个 AF 风险位点。最大的风险位点位于一个与肺静脉形成有关的基因附近;肺静脉的口部藏有引发 AF 的起始触发因素,而这些区域的隔离是 AF 消融治疗的基石。转录组学研究表明,AF 与细胞应激的受损或过度反应有关。双风险模型提出,在遗传易感个体中,对压力的转录反应不足会导致晚年发生 AF。针对代谢、氧化或蛋白质处理应激的药物可能是新型的上游药物,可以重新带回床边,用于研究预防 AF。